Amy Elazzouzi - 01 Sep 2026 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Reporting relationship: SVP, Finance & PAO
Issuer ticker: AURA
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Sep 2026, 17:23:08 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Grassi, as Attorney-in-Fact

Key filing fact

Amy Elazzouzi filed Form 4 for Aura Biosciences, Inc. (AURA) on 01 Sep 2026.

Key facts

This page summarizes Amy Elazzouzi's Form 4 filing for Aura Biosciences, Inc. (AURA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Sep 2026, 17:23.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002042910 Primary reporting owner

Elazzouzi Amy

Relationship: SVP, Finance & PAO
Address: C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON
Signature: /s/ Daniel Grassi, as Attorney-in-Fact
Signature date: 01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AURA transaction

Common Stock

Award

Transaction value
Shares: +23,540
Change %: +20%
Price: $0.000000^*
Shares after: 143,600
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +46,460
Change %
Price: $0.000000^*
Shares after: 46,460
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 46,460
Exercise price: $7.43
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027.

Footnote F2

The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026.